All Biosimilars Will Get Special Names, FDA Says
The U.S. Food and Drug Administration on Thursday said it will create special names to distinguish even the most sophisticated biosimilars from previously approved biologics, arguing that the move will protect...To view the full article, register now.
Already a subscriber? Click here to view full article